Drug Trial Radar · NCT05554406
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
335
Planned (sponsor's estimate)
Start
Sep 25, 2024
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Sep 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 59 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin.
Conditions
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
- Acute Myeloid Leukemia Post Cytotoxic Therapy
- Acute Myeloid Leukemia, Myelodysplasia-Related
Interventions
AzacitidineDrug
Given SC or IV
Biospecimen CollectionProcedure
Undergo collection of blood
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration
CytarabineDrug
Given IV
Daunorubicin HydrochlorideDrug
Given IV
Echocardiography TestProcedure
Undergo ECHO
Liposome-encapsulated Daunorubicin-CytarabineDrug
Given IV
Multigated Acquisition ScanProcedure
Undergo MUGA
VenetoclaxDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Minimal residual disease (MRD) response (Arm 1, 2, 4 and 5)Time frame: After induction (28 days) or re-induction (56 days)
- MRD response (Arm 3)Time frame: After two cycles of therapy (56 days)
Locations
227 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Recruiting
Mayo Clinic Hospital in Arizona
Phoenix, Arizona · Recruiting
Banner University Medical Center - Tucson
Tucson, Arizona · Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona · Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California · Active not recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Kaiser Permanente-Oakland
Oakland, California · Recruiting
Kaiser Permanente-Roseville
Roseville, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
UCSF Medical Center-Parnassus
San Francisco, California · Recruiting
Mills Health Center
San Mateo, California · Active not recruiting
Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Recruiting
Miami Cancer Institute
Miami, Florida · Recruiting
Memorial Hospital West
Pembroke Pines, Florida · Recruiting
Phoebe Putney Memorial Hospital
Albany, Georgia · Recruiting
Augusta University Medical Center
Augusta, Georgia · Recruiting
Hawaii Cancer Care - Westridge
‘Aiea, Hawaii · Recruiting
Pali Momi Medical Center
‘Aiea, Hawaii · Recruiting
Hawaii Cancer Care Inc - Waterfront Plaza
Honolulu, Hawaii · Recruiting
Straub Clinic and Hospital
Honolulu, Hawaii · Recruiting
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii · Recruiting
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho · Recruiting
Saint Luke's Cancer Institute - Boise
Boise, Idaho · Recruiting
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho · Recruiting
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho · Recruiting
Saint Luke's Cancer Institute - Fruitland
Fruitland, Idaho · Recruiting
Saint Luke's Cancer Institute - Meridian
Meridian, Idaho · Recruiting
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho · Recruiting
Saint Luke's Cancer Institute - Nampa
Nampa, Idaho · Recruiting
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho · Recruiting
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho · Recruiting
OSF Saint Joseph Medical Center
Bloomington, Illinois · Recruiting
Illinois CancerCare-Bloomington
Bloomington, Illinois · Recruiting
Illinois CancerCare-Canton
Canton, Illinois · Recruiting
Illinois CancerCare-Carthage
Carthage, Illinois · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Recruiting
Showing 40 of 227 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.